Comparative analysis of rule elements for transportation of cell therapy products among regulations and standards

Author:

Okamura Yoshihiko1ORCID,Kano Shingo1ORCID

Affiliation:

1. Bio-Innovation Policy Unit, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, University of Tokyo, Bioscience Bldg B1-17, 5-1-5, Kashiwanoha, Kashiwa City, Chiba 8562, Japan

Abstract

Aim: This study aimed to identify the elements involved in the transportation of cell therapy products by conducting a comparative analysis of four related international standards for temperature-controlled delivery and good distribution practice (GDP). Methods: An analytical framework was constructed to cover the entire transportation process. The descriptions of each element in the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC/S) GDP, International Organization for Standardization (ISO) 21973, Foundation for the Accreditation of Cellular Therapy Common Standards for Cellular Therapies and ISO 23412 were compared. Results: The study identified some elements that were present in the PIC/S GDP and other standards but were absent in ISO 21973, and vice versa. These elements are crucial in view of the increasing opportunities to transport allogeneic cells in the future. Conclusion: The study identified the necessary elements that should be included in the development of transport regulations for cell therapy products.

Publisher

Future Medicine Ltd

Subject

Embryology,Biomedical Engineering

Reference33 articles.

1. US Food and Drug Administration. Approval letter for tisagenlecleucel BLA (2017). www.fda.gov/media/106989/download

2. Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme. Guide to good manufacturing practice for medicinal products. part I (2022). https://picscheme.org/docview/4588

3. Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme. Guide to good manufacturing practice for medicinal products, part II (2022). https://picscheme.org/docview/4589

4. Ministry of Health, Labour and Welfare. Ministry Ordinance on good gene, cellular, and tissue-based products manufacturing practice (Japan) (2014). https://elaws.e-gov.go.jp/document?lawid=426M60000100093_20210801_503M60000100015

5. European Commission. Guidelines on Good Distribution Practice of Medicinal Products for Human Use. 2013/C 343/01 (2013). https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2013:343:0001:0014:EN:PDF

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3